A federal court has temporarily halted Louisiana’s legal effort to restrict nationwide access to the abortion medication mifepristone while President Donald Trump’s administration examines the drug’s safety protocols.
U.S. District Judge David Joseph, presiding in Lafayette, Louisiana, ruled Tuesday that the GOP-controlled state’s opposition to a 2023 federal regulation permitting mail delivery of mifepristone should be suspended until the Food and Drug Administration determines whether to withdraw the policy.
Judge Joseph rejected Louisiana’s request for an immediate injunction against the 2023 regulation but indicated the state may resubmit their request once proceedings continue.
“At this juncture, it is the completion of FDA’s promised good faith, evidence-based, and expeditious review [and] not ‘government by lawsuit’ that this Court finds to be in the public interest,” Joseph wrote.
The FDA initiated an examination of mifepristone last year, a medication initially authorized in 2000 that now accounts for 60% of pregnancy terminations in America. Reports suggest this review has been postponed until after November’s midterm elections.
Following the Supreme Court’s 2022 decision eliminating constitutional abortion protections, approximately half of all states have prohibited or significantly limited the procedure. This shift has increased demand for medication-based abortion methods, sparking numerous court battles over drug accessibility.
The medication abortion process involves two drugs – mifepristone followed by misoprostol – administered to end pregnancies within the first 10 weeks. The 2023 FDA regulation removed the previous mandate requiring in-person dispensing of these medications.
Republican Attorney General Liz Murrill’s office filed suit against the FDA in October, alleging the agency overlooked safety concerns when expanding mifepristone access. Five additional Republican-controlled states are pursuing more comprehensive legal challenges regarding mifepristone regulations, including the drug’s original 2000 approval.
The FDA requested the case suspension pending their review and has additionally contended that Louisiana lacks proper legal grounds to file the lawsuit.
Both Louisiana and Texas have initiated legal action or criminal charges against healthcare providers from other states who prescribe mifepristone to their residents, challenging protective “shield laws” in states like New York and California that safeguard providers from external investigations and prosecutions.
Pharmaceutical companies GenBioPro and Danco Laboratories have joined Louisiana’s case to support the FDA regulation. These companies stated in legal documents that no scientific data justifies overturning the FDA’s 2023 decision eliminating in-person dispensing requirements for mifepristone.
Danco Laboratories produces only the brand-name mifepristone product Mifeprex, while GenBioPro generates most of its income from the generic alternative, according to their court submissions.
